Company: NDRA
Filing Date: 2025-07-25
Form Type: S-1/A
Source: 0001654954-25-008477
Chunk: 20

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-07-25
Form: S-1/A
Chunk 20
---
 experience substantial dilution.

The shares being offered pursuant to this prospectus represent 15,700,000 shares of common stock being sold pursuant to this prospectus, and 628,000 shares of common stock issuable upon the exercise of the Underwriter Warrants (or 18,055,000 shares of common stock and 722,200 shares of common stock issuable upon the exercise of the Underwriter Warrants if the Underwriter exercises its over-allotment option in full). As of July 24, 2025, there were 752,755 shares of common stock issued and outstanding (prior to any deemed issuance of the Pre-Funded Warrants and the Underwriter Warrants). If we are required to issue the maximum number of shares of common stock that are being registered hereunder, the number of shares of common stock issued and outstanding after such issuance would represent approximately 2,170% of the number of shares of common stock issued and outstanding as of the date of this prospectus. As a result, an existing stockholder’s proportionate interest in us will be substantially diluted. The actual number of shares of common stock that we issue may be less than the aggregate number of shares covered by this prospectus.

Our stock price has fluctuated in the past, has recently been volatile and may be volatile in the future for reasons unrelated to our operating performance or prospects, and as a result, investors in our common stock could incur substantial losses.

Our stock price has fluctuated in the past, has recently been volatile and may be volatile in the future. From January 1, 2025 through July 24, 2025, intra-day trading prices of shares of our common stock on the Nasdaq Capital Market fluctuated from a low of $2.90 to a high of $11.96 and may continue to fluctuate significantly in the future. The stock market in general and the market for healthcare companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may experience losses on their investment in our common stock. Additionally, we intend to use the majority of the proceeds from this offering to purchase cryptocurrency, which has been, and will likely continue to be, volatile. When a material portion of our assets is represented by cryptocurrency, our stock price will likely fluctuate based on the price of cryptocurrency. See the risk factor below titled,“We may use the net proceeds or a portion thereof from any offering by the Company to purchase additional